(5R)-5-hydroxytriptolide (LLDT-8), a novel immunosuppressant in clinical trials, exhibits potent antitumor activity via transcription inhibition

Cancer Letters

Volumn 324, Issue 1, 2012, Pages 75-82

  Wang, Lei ^a   Xu, Yongping ^a   Fu, Li ^a   Li, Yuanchao ^a   Lou, Liguang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

(5R) 5 hydroxytriptolide; Transcription inhibition; Triptolide

Indexed keywords

5 HYDROXYTRIPTOLIDE; ANTINEOPLASTIC AGENT; BETA TUBULIN; CASPASE 8; CASPASE 9; CISPLATIN; DOXORUBICIN; GLYCOPROTEIN P; HEAT SHOCK PROTEIN 70; IMMUNOSUPPRESSIVE AGENT; LLDT 8; MESSENGER RNA; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; TRIPTOLIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; TRANSCRIPTION TERMINATION; TREATMENT DURATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DITERPENES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, NUDE; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PROSTATIC NEOPLASMS; S PHASE; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84864033203     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.05.004     Document Type: Article

References (36)

1. te Poele R.H., Okorokov A.L., Joel S.P. RNA synthesis block by 5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells. Oncogene 1999, 18:5765-5772.
2. Chang T.C., Tsai L.C., Hung M.W., Chu L.L., Chu J.T., Chen Y.C. Effects of transcription and translation inhibitors on a human gastric carcinoma cell line. Potential role of Bcl-X(S) in apoptosis triggered by these inhibitors. Biochem. Pharmacol. 1997, 53:969-977.
3. Koumenis C., Giaccia A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol. Cell Biol. 1997, 17:7306-7316.
4. Darnell J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2:740-749.
5. Sobell H.M. Actinomycin and DNA transcription. Proc. Natl. Acad. Sci. USA 1985, 82:5328-5331.
6. Turan T., Karacay O., Tulunay G., Boran N., Koc S., Bozok S., Kose M.F. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int. J. Gynecol. Cancer 2006, 16:1432-1438.
7. Abd El-Aal H.H., Habib E.E., Mishrif M.M. Wilms' tumor: the experience of the pediatric unit of Kasr El-Aini center of radiation oncology and nuclear medicine (NEMROCK). J. Egypt Natl. Cancer Inst. 2005, 17:308-314.
8. Khatua S., Nair C.N., Ghosh K. Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues. J. Pediatr. Hematol. Oncol. 2004, 26:777-779.
9. Adams D.J., Knick V.C. P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine). Invest. New Drugs 1995, 13:13-21.
10. Blagosklonny M.V. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 2004, 3:1537-1542.
11. Chen B.J. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk. Lymphoma 2001, 42:253-265.
12. Titov D.V., Gilman B., He Q.L., Bhat S., Low W.K., Dang Y., Smeaton M., Demain A.L., Miller P.S., Kugel J.F., Goodrich J.A., Liu J.O. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat. Chem. Biol. 2011, 7:182-188.
13. Shao F., Wang G., Xie H., Zhu X., Sun J., Jiye A. Pharmacokinetic study of triptolide, a constituent of immunosuppressive Chinese herb medicine, in rats. Biol. Pharm. Bull. 2007, 30:702-707.
14. Liu J., Jiang Z., Liu L., Zhang Y., Zhang S., Xiao J., Ma M., Zhang L. Triptolide induces adverse effect on reproductive parameters of female Sprague-Dawley rats. Drug Chem. Toxicol. 2011, 34:1-7.
15. Ni B., Jiang Z., Huang X., Xu F., Zhang R., Zhang Z., Tian Y., Wang T., Zhu T., Liu J., Zhang L. Male reproductive toxicity and toxicokinetics of triptolide in rats. Arzneimittelforschung 2008, 58:673-680.
16. Zhou R., Zhang F., He P.L., Zhou W.L., Wu Q.L., Xu J.Y., Zhou Y., Tang W., Li X.Y., Yang Y.F., Li Y.C., Zuo J.P. (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide analog mediates immunosuppressive effects in vitro and in vivo. Int. Immunopharmacol. 2005, 5:1895-1903.
17. Zhou R., Zheng S.X., Tang W., He P.L., Li X.Y., Yang Y.F., Li Y.C., Geng J.G., Zuo J.P. Inhibition of inducible nitric-oxide synthase expression by (5R)-5-hydroxytriptolide in interferon-gamma- and bacterial lipopolysaccharide-stimulated macrophages. J. Pharmacol. Exp. Ther. 2006, 316:121-128.
18. Zhao H., Quan H., Xie C., Xu Y., Xie F., Hu Y., Lou L. YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance. Cancer Lett. 2012, 314:54-62.
19. Theodorakis N.G., Drujan D., De Maio A. Thermotolerant cells show an attenuated expression of Hsp70 after heat shock. J. Biol. Chem. 1999, 274:12081-12086.
20. Leresche A., Wolf V.J., Gottesfeld J.M. Repression of RNA polymerase II and III transcription during M phase of the cell cycle. Exp. Cell Res. 1996, 229:282-288.
21. Fu Y.F., Zhu Y.N., Ni J., Zhong X.G., Tang W., Zhou R., Zhou Y., Dong J.R., He P.L., Wan H., Li Y.C., Yang Y.F., Zuo J.P. (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation. J. Neuroimmunol. 2006, 175:142-151.
22. Ren Y.X., Zhou R., Tang W., Wang W.H., Li Y.C., Yang Y.F., Zuo J.P. (5R)-5-hydroxytriptolide (LLDT-8) protects against bleomycin-induced lung fibrosis in mice. Acta Pharmacol. Sin. 2007, 28:518-525.
23. Tang W., Yang Y., Zhang F., Li Y.C., Zhou R., Wang J.X., Zhu Y.N., Li X.Y., Yang Y.F., Zuo J.P. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells. Int. Immunopharmacol. 2005, 5:1904-1913.
24. Tang W., Zhou R., Yang Y., Li Y.C., Yang Y.F., Zuo J.P. Suppression of (5R)-5-hydroxytriptolide (LLDT-8) on allograft rejection in full MHC-mismatched mouse cardiac transplantation. Transplantation 2006, 81:927-933.
25. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
26. Gao Z., Garcia-Echeverria C., Jensen M.R. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. Curr. Opin. Drug. Discov. Devel. 2010, 13:193-202.
27. Shankar S., Srivastava R.K. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv. Exp. Med. Biol. 2008, 615:261-298.
28. Shah M.A., Schwartz G.K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 2001, 7:2168-2181.
29. Agarwal R., Kaye S.B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3:502-516.
30. Meads M.B., Gatenby R.A., Dalton W.S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 2009, 9:665-674.
31. Junhua L., Zhanghua H. Tripterygium wilfordii treating the post-operation cases of endometriosis. J. Clin. Med. Off. 2002, 35:430-432.
32. Yuping G., Defu C. Clinical study on effect of Tripterygium Wilfordii Hook. f. on Uterin Leiomyoma. Chin. J. Obstet. Gynecol. 2000, 35.
33. Haipeng Z., Xiaoke Z., Youqiong W. Pharmacologic actions and prospects on Tripterygium wilfordii. J. Grad. Sun Yat-Sen Univ. (Nat. Sci., Med.) 2010, 31:5-8.
34. Yusuf R.Z., Duan Z., Lamendola D.E., Penson R.T., Seiden M.V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr. Cancer Drug Targets 2003, 3:1-19.
35. DiSalvo T.G., Narula J., Cosimi A.B., Keck S., Dec G.W., Semigran M.J. Actinomycin D is an effective adjunctive immunosuppressive agent in recurrent cardiac allograft rejection. J. Heart Lung Transplant. 1995, 14:955-962.
36. Novak K. Swinging the vote for rapamycin. Nat. Rev. Cancer 2002, 2:75.